Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology, UCLouvain, Université Catholique de Louvain , Brussels, Belgium.
Department of Medicine, University of California San Diego , La Jolla, CA, USA.
Gut Microbes. 2020 Nov 9;12(1):1782157. doi: 10.1080/19490976.2020.1782157. Epub 2020 Jun 26.
Animal data suggest a role of the gut-liver axis in progression of alcoholic liver disease (ALD), but human data are scarce especially for early disease stages.
We included patients with alcohol use disorder (AUD) who follow a rehabilitation program and matched healthy controls. We determined intestinal epithelial and vascular permeability (IP) (using urinary excretion of Cr-EDTA, fecal albumin content, and immunohistochemistry in distal duodenal biopsies), epithelial damage (histology, serum iFABP, and intestinal gene expression), and microbial translocation (Gram - and Gram + serum markers by ELISA). Duodenal mucosa-associated microbiota and fecal microbiota were analyzed by 16 S rRNA sequencing. ALD was staged by Fibroscan® (liver stiffness, controlled attenuation parameter) in combination with serum AST, ALT, and CK18-M65.
Only a subset of AUD patients had increased Cr-EDTA and fecal albumin together with disrupted tight junctions and vasculature expression of plasmalemma Vesicle-Associated Protein-1. The so-defined increased intestinal permeability was not related to changes of the duodenal microbiota or alterations of the intestinal epithelium but associated with compositional changes of the fecal microbiota. Leaky gut alone did not explain increased microbial translocation in AUD patients. By contrast, duodenal dysbiosis with a dominance shift toward specific potential pathogenic bacteria genera (), increased IP and elevated markers of microbial translocation characterized AUD patients with progressive ALD (steato-hepatitis, steato-fibrosis).
Progressive ALD already at early disease stages is associated with duodenal mucosa-associated dysbiosis and elevated microbial translocation. Surprisingly, such modifications were not linked with increased IP. Rather, increased IP appears related to fecal microbiota dysbiosis.
动物研究表明肠道-肝脏轴在酒精性肝病(ALD)的进展中起作用,但人体数据,尤其是在疾病早期阶段的数据非常有限。
我们纳入了正在接受康复治疗的酒精使用障碍(AUD)患者,并匹配了健康对照组。我们测定了肠道上皮和血管通透性(IP)(通过尿 Cr-EDTA 排泄、粪便白蛋白含量和远端十二指肠活检的免疫组化)、上皮损伤(组织学、血清 iFABP 和肠道基因表达)和微生物易位(通过 ELISA 检测革兰氏阴性和革兰氏阳性血清标志物)。通过 16S rRNA 测序分析十二指肠黏膜相关微生物群和粪便微生物群。使用 Fibroscan®(肝硬度、受控衰减参数)结合血清 AST、ALT 和 CK18-M65 对 ALD 进行分期。
只有一部分 AUD 患者出现 Cr-EDTA 和粪便白蛋白增加,同时紧密连接和质膜囊泡相关蛋白 1 的血管表达受到破坏。这种定义的肠道通透性增加与十二指肠微生物群的变化或肠道上皮的改变无关,而是与粪便微生物群的组成变化有关。渗漏的肠道本身并不能解释 AUD 患者中微生物易位的增加。相比之下,以特定潜在致病性细菌属为主导的十二指肠菌群失调、IP 增加和微生物易位标志物升高,是伴有进展性 ALD(脂肪性肝炎、脂肪性纤维化)的 AUD 患者的特征。
在疾病早期阶段,进展性 ALD 与十二指肠黏膜相关菌群失调和微生物易位增加有关。令人惊讶的是,这种改变与 IP 增加无关。相反,IP 增加似乎与粪便微生物群失调有关。